Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?

NCT ID NCT06263231

Recruiting now Disease control Sponsor: Intensity Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether an investigational drug called INT230-6, which combines three anti-cancer agents and is injected directly into tumors, can help people with advanced soft tissue sarcoma live longer than those receiving standard care. The study enrolls adults with specific sarcoma subtypes—liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma—that have progressed after up to two prior therapies. Participants are randomly assigned to receive either INT230-6 or one of the standard treatments (eribulin, trabectedin, or pazopanib). The main goal is to compare overall survival between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INT230-6, a combination of cisplatin, vinblastine, and SHAO, injected directly into tumors
What this could lead to: If successful, this approach could offer a new treatment option that may extend survival for people with advanced soft tissue sarcoma who have limited choices after standard therapies fail.
What could go wrong: This is a phase 3 trial, but the outcome is uncertain. The drug may not improve survival over standard care, and side effects from the chemotherapy components could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma liposarcoma sarcoma soft tissue sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA,SOFT TISSUE

Contacts and locations

Locations

Centre Leon Berard
RECRUITING

Lyon, 69008, France
Centro Integral Oncologico Clara Campal (HM CIOCC)
RECRUITING

Madrid, 28050, Spain
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Helios Klinikum Bad Saarow
RECRUITING

Bad Saarow, 15526, Germany
Hospital Universitari Vall Hebron
RECRUITING

Barcelona, 08740, Spain
Hospital de la Santa Creu i Sant Pau
RECRUITING

Barcelona, 08025, Spain
Nebraska Methodist Hospital
RECRUITING

Omaha, Nebraska, 68114, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Profound Research LLC
RECRUITING

Farmington Hills, Michigan, 48333, United States
Sarcoma Oncology Center
RECRUITING

Santa Monica, California, 90403, United States
Temple University - Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
The James Cancer Hospital and Solove Research Institute
RECRUITING

Columbus, Ohio, 43210, United States
USC/Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
University of California Los Angeles (UCLA) - Santa Monica Cancer Care
RECRUITING

Santa Monica, California, 90404, United States
University of Pennsylvania - Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19106, United States
Universitäres Krebszentrum (UCCL)
RECRUITING

Leipzig, 04103, Germany
Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location
RECRUITING

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.